Tp53 inhibition can suppress neuroepithelial apoptosis and substantially rescue cranioskeletal development in polr1c-/- and polr1d-/- mutant embryos providing a potential avenue for the therapeutic prevention of TCS. This evidence concerns the gene POLR1C and Treacher-Collins syndrome.